Streetbeat News

BIVI

BioVie Inc.

https://bioviepharma.com

Industry

Biotechnology

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.

Open

3.35

Mkt cap

57M

Volume

2.4M

High

3.35

P/E Ratio

-0.44

52-wk high

58.20

Low

2.97

Div yield

N/A

52-wk low

1.04

BioVie's short interest has decreased by 50.95%, with 187,000 shares sold short, representing 3.37% of its float. This is below the peer group average of 3.44%. The decrease in short interest may indicate a more bullish sentiment towards the stock.

Portfolio Pulse from Benzinga Insights

October 31, 2024 | 5:15 pm

BioVie has announced a registered direct offering of 1.15 million shares at $2.83 per share, aiming to raise approximately $3.2 million in gross proceeds. The closing of this offering is expected on October 29, 2024.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 7:19 pm

The article highlights the pre-market movements of various healthcare stocks on Friday. TFF Pharmaceuticals, Centene, and Nexalin Technology are among the gainers, while Monopar Therapeutics and Quince Therapeutics are notable losers.

Portfolio Pulse from Benzinga Insights

October 25, 2024 | 12:08 pm

The article highlights the pre-market movements of several healthcare stocks. TFF Pharmaceuticals, Centene, and Nexalin Technology are among the gainers, while Monopar Therapeutics and Quince Therapeutics are notable losers.

Portfolio Pulse from Benzinga Insights

October 25, 2024 | 12:07 pm

In Thursday's pre-market session, several healthcare stocks experienced significant movements. Notable gainers included Tevogen Bio Holdings, CNS Pharma, and DBV Technologies, while Conduit Pharmaceuticals, Genprex, and Ensysce Biosciences were among the losers.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 12:07 pm

In Thursday's pre-market session, several health care stocks experienced significant price movements. Notable gainers included Tevogen Bio Holdings, CNS Pharma, and DBV Technologies, while Conduit Pharmaceuticals, Genprex, and Ensysce Biosciences were among the losers.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 12:07 pm

Several healthcare stocks experienced significant price movements in Wednesday's after-market session. CNS Pharma, DBV Technologies, and Molina Healthcare were among the gainers, while Enveric Biosciences and Evotec saw declines. Molina Healthcare's rise is linked to its Q3 earnings release.

Portfolio Pulse from Benzinga Insights

October 23, 2024 | 8:31 pm

BioVie shares fell after the company announced a registered direct offering and concurrent private placement, raising $6 million by selling 2.67 million shares at $2.25 each.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 7:58 pm

BioVie shares have resumed trading after a temporary halt. This development is significant for investors as it may impact the stock's short-term price movement.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 7:34 pm

BioVie shares experienced a significant drop, triggering a circuit breaker halt as the stock fell by 5.95%.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 7:27 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.